ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Hanyang, Seoul, KOR:

Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (ASSURE)

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Seoul, Korea, Republic of and 108 other locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Seoul, Korea, Republic of and 108 other locations

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (TUSCANY)

in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...

Enrolling
Leukemia, Myeloid, Acute
Chronic Myelomonocytic Leukemia
Drug: Venetoclax Oral Tablet
Drug: Tuspetinib

Phase 1, Phase 2

Aptose Biosciences

Seoul, Korea, Republic of and 33 other locations

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...

Active, not recruiting
Acute Myeloid Leukemia
Drug: S65487 and azacitidine

Phase 1, Phase 2

Servier
Servier

Seoul, Korea, Republic of and 10 other locations

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling
Myeloid Leukemia, Philadelphia Positive
Drug: Asciminib Adult formulation group
Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis
Novartis

Seoul, Korea, Republic of and 37 other locations

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

Seoul, Korea, Republic of and 85 other locations

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...

Enrolling
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase
Drug: TERN-701

Phase 1

Terns Pharmaceuticals

Anyang-si, Gyeonggido, Korea, Republic of and 39 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

Uijeongbu si, Gyeonggi Do, Korea, Republic of and 120 other locations

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Seoul, Korea, Republic of and 125 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

Seoul, Korea, Republic of and 48 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems